Salas Eduardo Rene 4

What Happened

• Eduardo Rene Salas, a director of ADMA BIOLOGICS (ADMA), received equity awards on February 9, 2026: 10,690 restricted stock units (RSUs) and an additional 17,730 RSU-type derivative awards, for a total of 28,420 units. The awards were granted at $0.00 (no cash exchanged). The RSUs vest in installments over one year (see footnotes).

Key Details

• Transaction date: February 9, 2026; Form 4 filed February 11, 2026 (appears timely—filed within two business days).
• Grant amounts/prices: 10,690 RSUs @ $0.00 (award); 17,730 derivative RSUs @ $0.00 (award/derivative).
• Vesting: Footnote F1—these RSUs vest in two equal installments at the 6- and 12-month anniversaries of grant (fully vested at one year, subject to continued service).
• Shares/units reported after the transaction (per footnote F2): includes the 10,690 RSUs granted 2/9/2026 (vest by 2/9/2027), 5,445 remaining RSUs from a 2/19/2025 grant (vest 2/19/2026), and 5,444 shares of common stock owned by Mr. Salas.
• No cash proceeds (not a purchase or sale); this is an equity compensation grant.
• Footnote F3 notes other option vesting schedules (monthly over one year) for relevant awards, though no option exercise was reported in this filing.

Context

• RSUs are deferred equity awards that convert into shares only when they vest; they are compensation, not a market purchase or sale. Because no shares were sold or bought on the open market, this filing is not a liquidity signal but rather routine director compensation subject to service-based vesting.